FRANCE/BELGIUM - Ablynx and Boehringer Ingelheim join forces

Ablynx, the biopharmaceutical company who specialise in the discovery and development of Nanobodies®, expects to receive payments of up to EUR 75m during the research term, including a EUR 15m equity investment by Boehringer Ingelheim. In addition, for each Nanobody® which is developed, Ablynx will receive up to EUR 125m and undisclosed royalties in milestone payments. The development, manufacture and commercialisation of any products resulting from the collaboration will be the exclusive responsibility of Boehringer Ingelheim, although Ablynx will have certain co-promotion rights in Europe.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• France
• Benelux